Kratom Use and Toxicities in the United States

被引:65
作者
Eggleston, William [1 ,2 ]
Stoppacher, Robert [3 ]
Suen, Kyle [2 ]
Marraffa, Jeanna M. [2 ,4 ]
Nelson, Lewis S. [5 ]
机构
[1] SUNY Binghamton, Sch Pharm & Pharmaceut Sci, POB 6000, Binghamton, NY 13902 USA
[2] SUNY Upstate Med Univ, Dept Emergency Med, Syracuse, NY 13210 USA
[3] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA
[4] Upstate New York Poison Ctr, Syracuse, NY USA
[5] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ USA
来源
PHARMACOTHERAPY | 2019年 / 39卷 / 07期
关键词
opioid use disorder; opioids; kratom; MITRAGYNINE;
D O I
10.1002/phar.2280
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Kratom is an herbal supplement containing alkaloids with opioid properties. This review was conducted to determine toxicities associated with kratom use in the United States in order to provide insight into its safety as a dietary supplement. Methods We conducted a retrospective review of kratom exposures reported to the National Poison Data System to determine the toxicities associated with kratom use. We also reviewed records from a county medical examiner's office in New York State to identify kratom-associated fatalities. Results A total of 2312 kratom exposures were reported, with 935 cases involving kratom as the only substance. Kratom most commonly caused agitation (18.6%), tachycardia (16.9%), drowsiness (13.6%), vomiting (11.2%), and confusion (8.1%). Serious effects of seizure (6.1%), withdrawal (6.1%), hallucinations (4.8%), respiratory depression (2.8%), coma (2.3%), and cardiac or respiratory arrest (0.6%) were also reported. Kratom was listed as a cause or contributing factor in the death of four decedents identified by the county medical examiner's office. Conclusions Kratom use is increasing and is associated with significant toxicities. Our findings suggest kratom is not reasonably expected to be safe and poses a public health threat due to its availability as an herbal supplement.
引用
收藏
页码:775 / 777
页数:3
相关论文
共 9 条
  • [1] [Anonymous], 2018, Or. Stat, p581
  • [2] Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)
    Boyer, Edward W.
    Babu, Kavita M.
    Adkins, Jessica E.
    McCurdy, Christopher R.
    Halpern, John H.
    [J]. ADDICTION, 2008, 103 (06) : 1048 - 1050
  • [3] Patterns of Kratom use and health impact in the US-Results from an online survey
    Grundmann, Oliver
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 176 : 63 - 70
  • [4] Discriminative stimulus properties of mitragynine (kratom) in rats
    Harun, Norsyifa
    Hassan, Zurina
    Navaratnam, Visweswaran
    Mansor, Sharif M.
    Shoaib, Mohammed
    [J]. PSYCHOPHARMACOLOGY, 2015, 232 (13) : 2227 - 2238
  • [5] Dietary supplements: How they are used and regulated
    Hathcock, J
    [J]. JOURNAL OF NUTRITION, 2001, 131 (03) : 1114S - 1117S
  • [6] Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine
    Lydecker A.G.
    Sharma A.
    McCurdy C.R.
    Avery B.A.
    Babu K.M.
    Boyer E.W.
    [J]. Journal of Medical Toxicology, 2016, 12 (4) : 341 - 349
  • [7] Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program
    Smith, Kirsten Elin
    Lawson, Thomas
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 180 : 340 - 348
  • [8] Trakulsrichai S, 2015, DRUG DES DEV THER, V9, P2421, DOI [10.2147/DDDT.579658, 10.2147/DDDT.S79658]
  • [9] The pharmacology and toxicology of kratom: from traditional herb to drug of abuse
    Warner, Marcus L.
    Kaufman, Nellie C.
    Grundmann, Oliver
    [J]. INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2016, 130 (01) : 127 - 138